SCHEMBL3327593

SCHEMBL3327593

Cn1nccc1-c1ccc(C(=O)O)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.54
KDM4C Q9H3R0 3/20 0.54
KDM5B Q9UGL1 3/20 0.54
KDM4A O75164 1/20 0.54
AKT1 P31749 6/20 0.52
AKT2 P31751 1/20 0.52
ADH5 P11766 2/20 0.46
SLC22A12 Q96S37 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KDM2B Q8NHM5 1/20 0.42
HTR2A P28223 2/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
RARB P10826 2/20 0.41
RORC P51449 1/20 0.40
RARA P10276 1/20 0.40
RARG P13631 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3331818 0.82 ALDH1A1 (0.41) KDM5AKDM4CKDM5BKDM4AAKT1
SCHEMBL20438984 0.79 AKT1 (0.49) KDM5AKDM4CKDM5BKDM4AAKT1
SCHEMBL3487966 0.78 KDM4A (0.48) KDM5AKDM4CKDM5BKDM4AAKT1
SCHEMBL14189702 0.75 SCN9A (0.42) KDM5AKDM4CKDM5BKDM4AAKT1
SCHEMBL31148268 0.75 ALDH1A1 (0.42) KDM5AKDM4CKDM5BKDM4AAKT1
SCHEMBL16502576 0.75 TTK (0.44) KDM5AKDM4CKDM5BKDM4ASLC22A12
SCHEMBL29790132 0.75 AKT1 (0.45) KDM5AKDM4CKDM5BAKT1AKT2
SCHEMBL2595459 0.75 HDAC3 (0.45) ADH5SLC22A12RAB9AALDH1A1RORC
SCHEMBL18952445 0.75 AKT1 (0.45) KDM5AKDM4CKDM5BAKT1AKT2
SCHEMBL14213193 0.75 LMNA (0.57) ADH5SLC22A12LMNAMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338434-B2 Inhibitors of Akt activity GLAXOSMITHKLINE LLC (US) 2012-12-25 US disclosed
US-8338434-B2 Inhibitors of Akt activity GLAXOSMITHKLINE LLC (US) 2012-12-25 US disclosed
US-8338434-B2 Inhibitors of Akt activity GLAXOSMITHKLINE LLC (US) 2012-12-25 US disclosed
US-20100137338-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2010-06-03 US disclosed
US-20100137338-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2010-06-03 US disclosed
US-20100137338-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION 2010-06-03 US disclosed
EP-2134175-A1 INHIBITORS OF AKT ACTIVITY Smithkline Beecham Corporation (US) 2009-12-23 EP disclosed
WO-2008121786-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-10-09 WO disclosed
WO-2008121786-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137338-A1 INHIBITORS OF Akt ACTIVITY PI4KB, AKT3, AKT2 KDM5A 3103/4885KDM4C 3863/4885KDM5B 2497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.